En la esclerosis sistémica, el esófago se afecta en un 90%, seguido de los tramos anorrectal (%), gástrico ( 70%), colon (%) e intestino delgado. La esclerodermia es un relativamente infrecuente enfermedad reumática autoinmunitaria que afecta la piel y otros órganos del cuerpo. La esclerosis sistémica es una enfermedad autoinmune del tejido conectivo, que se caracteriza por un depósito excesivo de tejido colágeno y otros.
|Country:||Antigua & Barbuda|
|Published (Last):||23 April 2009|
|PDF File Size:||6.83 Mb|
|ePub File Size:||16.87 Mb|
|Price:||Free* [*Free Regsitration Required]|
Systemic sclerosis is an autoimmune disease of the connective tissue characterized by an excessive deposit of collagen and other components of the extracellular matrix in the skin as well as in other internal organs, mainly in lung, gastrointestinal tract and kidney.
Digital ulcers are considered by their morbidity as severe and frequent complication in systemic sclerosis. These lesions are extremely painful, heal slowly and lead to substantial functional disability. The pathogenesis of digital ulcers differs depending on their location and occurs in up to half of all patients with limited or diffuse systemic sclerosis at some point during their disease.
Hemorragia por telangiectasias en paciente con esclerosis sistémica
Recent studies have demonstrated a correlation between the nailfold capillaroscopic pattern and the peripheral vascular involvement as well as with digital ulcers. Treatment includes pharmalogical and non-pharmacological measures, mainly based on controlling each of the mechanisms involved in their genesis and optimal treatment of the Raynaud phenomenon. Treatment includes pharmalogical and non-pharmacological measures, mainly based on controlling each of the mechanisms involved in their genesis and optimal treatment of the Raynaud phenomenon.
Mechanisms and consequences of fibrosis in systemic sclerosis [review]. Nat Clin Pract Rheumatol, 2pp. Systemic sclerosis hypothesis-driven treatment strategies [review].
Lancet,pp. Digital ulceration and critical digital ischemia in scleroderma. Scleroderma Care and Research, 1pp. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
Mol Immunol, 42pp. Altered blood B lymphocyte homeostasis in systemic sclerosis: Arthritis Rheum, 50pp. Pathogenesis of systemic sclerosis: J Dermatol Sci, 39pp. Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep, 7pp. Increased collagen synthesis by scleroderma fibroblasts in vitro A possible defect in the regulation or activation of the scleroderma fibroblast.
J Clin Invest, 54pp. Medicine Baltimore81pp. Patient perception of UK scleroderma services Results of an anonymous questionnaire.
Rheumatology, 45pp. Symptoms of Raynaud phenomenon in an escleerosis African-American community. J Clin Epidemiol, 52pp. Geographic variation in the prevalence of Raynaud phenomenon. J Reumatol, 20pp.
Prevalence of Raynaud phenomenon in general practice in the east of Spain. Clin Rheumatol, 20pp. Prevalence of Raynaud’s phenomenon in a healthy Spanish population. J Rheumatol, 20pp. The natural history of systemic lupus erythematosus by prospective analysis. Medicine Baltimore50pp. Medicine Baltimore64pp. De la Red, V. Prevalence and clinical characteristics in a series of patients.
J Rheumatol, 29pp. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol, 35pp. Curr Opin Rheumatol, 12pp. Pediatrics, 83pp. N Engl J Med,pp. Ewclerosis outcome in mixed connective tissue disease: Arthritis Rheum, 42pp. Rheum Dis Clin North Am, 22pp. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis, 67pp.
Autoimmunity Reviews, 6pp. Microvascular involvement in Systemic Sclerosis: Semin Arthritis Rheum, 30pp. Microvascular abnormalities as possible predictors escoerosis disease subset in Raynaud’s phenomenon and early connective tissue disease. Clin Exp Rheumatol, 1pp.
Evolution of primary Raynaud’s phenomenon to connective tissue disease. Arthritis Rheum, 28pp. Differentiation between primary and secondary Raynaud phenomenon. Ann Rheum Dis, 60 escelrosis, pp. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum, 23pp. Diagnostic significance of nailfold capillary patterns in patients with Raynaud’s phenomenon.
J Rheumatol, 13pp. Nailfold capillaroscopy in the screening and diagnosis of Raynaud’s phenomenon. Angiology, 45pp. Digital blood flow and nailfold capillary microscopy in Raynaud’s phenomenon.
There was a problem providing the content you requested
Arthritis Rheum, 16pp. Med Clin Barc89pp. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis.
J Rheumatol, 27pp. Nailfold capillaroscopy in Henoch-Schonlein purpura: J Pediatr,pp. La videocapillaroscopia periungueale nella sclerosis sistemica: Reumatismo, 56pp. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
Rheumatology, 43pp. Nailfold video-capillaroscopy in systemic-sclerosis. Z Rheumatol, 63pp. Assessment of nailfold capillaroscopy by x30 digital epiluminiscence dermoscopy in patients with Raynaud phenomenon. Br J Dermatol,pp. Nailfold digital capillaroscopy in patients with connective tissue disease and Raynaud’s disease. J Eur Acat Dermatol Venerol, 18pp. Raynaud’s phenomenon in mixed connective tissue disease. Rheum Dis Clin N Am, 31pp. Assessment of microvascular changes in Raynaud’s phenomenon and connective tissue disease using colour Doppler ultrasound.
Rheumatology, 39pp. Scleroderma patients nailfold videocapillarooscopic escleosis associated with disease subset and esclegosis severity. Rheumatology, 10pp. Raynaud’s Phenomenon and the role of capillaroscopy. Arthritis Rheum, 48pp. Therapeutic options for digital ulcers in patients with systemic sclerosis [review]. JDDG, 5pp. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol, 25pp.
Ulcere digitali in una coorte di pazienti sclerodermici. Reumatismo, 59pp. Medicine, 81pp. Clinical risk assessment of organ manifestations in systemic sclerosis. Ann Rheum Dis, 66pp.